https://orcid.org/0000-0002-0517-5390
References
- Ashour ML, Youssef FS, Gad HA, Wink M. 2017. Inhibition of cytochrome P450 (CYP3A4) activity by extracts from 57 plants used in traditional Chinese medicine (TCM). Pharmacogn Mag. 13(50):300–308.
- Huang SM, Temple R, Throckmorton DC, Lesko LJ. 2007. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 81(2):298–304.
- Juárez Olguín H, Calderón Guzmán D, Hernández García E, Barragán Mejía G. 2016. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev. 2016:9730467.
- Lagorce D, Douguet D, Miteva MA, Villoutreix BO. 2017. Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. Sci Rep. 7:46277.
- Math SB, Srinivasaraju R. 2010. Indian Psychiatric epidemiological studies: learning from the past. Indian J Psychiat. 52(Suppl 1):S95–S103.
- Rendic S, Di Carlo FJ. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 29(1-2):413–580.
- Sabarathinam S, Rajappan Chandra SK, Thangavel Mahalingam V. 2021. CYP3A4 mediated pharmacokinetics drug interaction potential of Maha-Yogaraj Gugglu and E, Z guggulsterone. Sci Rep. 11(1):715.
- Shashank Shekhar M, Neeraj K, Hamendra Pratap S, Shashi R, Chandra Shekhar Sharma S. 2018. In-silico pharmacokinetic, bioactivity and toxicity study of some selected anti-asthmatic agents. Int J Pharmaceut Sci Drug Res. 07/01:10.
- Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45(12):2615–2623.